focus -WSS

focus

author：Wikipedia 2025-09-14 09:59:06 - browse：1

A new treatment for Alzheimer’s disease developed by Eli Lilly slowed patients’ rate of cognitive and functional decline by 35% compared to placebo, the company said Wednesday, paving the way for a submission to the Food and Drug Administration and boosting hopes for a new class of Alzheimer’s drugs.

But the positive outcome of the study involving the drug, called donanemab, could be tempered by the deaths of two patients, and possibly a third, from a type of brain swelling caused by these drugs.

The results of the study were reported in a press release and have not yet been reviewed by outside scientists. Lilly said the data will be used to file for full approval with the FDA before the end of June. If cleared, donanemab will compete with another new Alzheimer’s treatment, Leqembi, made by Eisai and Biogen, that secured FDA approval in January.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： FDA approval of Sarepta Duchenne genetic therapy gives me hope
Next article： UnitedHealth CEO's Medicaid comments send insurer stocks diving

hotspot

WSS

For pregnant people, addiction treatment shouldn't mean a call to child protective services

Eli Lilly’s Zepbound improved liver scarring in mid

FDA's Woodcock to retire early next year

'Little Tech' descents on D.C., wanting a say in how AI is regulated

Readout Newsletter: The latest at Gilead, Catalent, and the NIH

Delfi Diagnostics unveils key aspects of liquid biopsy test for lung cancer

leisure time

focus

leisure time

Bright Health sells Medicare Advantage business to Molina

Novartis is flashing warning signs about its newly acquired myelofibrosis drug

The Supreme Court will review a ruling striking down a domestic violence federal gun ban

ASCO Takeaways: Winners, snoozers, and the art of cancer care

Moonlake's readout produced a cash windfall. Risks remain

Anthos stroke drug appears safer than common blood thinner

Medical records are filled with copy

Eli Lilly’s Zepbound improved liver scarring in mid

Apple is now the first public company to be valued at $3 trillion

Data don't support strong claims for Covid

leisure time

Wegovy, Zepbound and weight loss drugs that preserve muscle

An outdated Medicare rule harms dementia patients with anxiety

Fight over Supreme Court dialysis ruling puts kidney patients at risk

Stopping antidepressants leads to symptoms for 1 in 6 patients

Eli Lilly’s Zepbound improved liver scarring in mid

Anthos stroke drug appears safer than common blood thinner

Wikipedia

focus

hotspot

hotspot